Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)

Condition:   Sickle Cell Disease Interventions:   Drug: Motixafortide;   Drug: Natalizumab;   Procedure: Leukapheresis Sponsors:   Washington University School of Medicine;   BioLineRx, Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials